- Andelyn Biosciences has entered into a License Agreement with the Broad Institute to incorporate MyoAAV plasmids into its AAV Curator™ Platform.
- The MyoAAV plasmids offer enhanced efficiency in targeting muscle tissue and de-target the liver, potentially reducing dosing requirements.
Andelyn Biosciences, a cell and gene therapy CDMO, has secured a License Agreement with the Broad Institute to integrate MyoAAV plasmids into its AAV Curator™ Platform. Announced on August 7, 2024, this new addition aims to improve the efficiency of gene therapies by enhancing targeting capabilities.
The MyoAAV plasmids, developed by the Broad Institute, are designed to produce adeno-associated viruses (AAVs) that are ten times more effective at reaching muscle tissue compared to traditional vectors. They also reduce targeting to the liver, which can lead to lower dosing requirements for therapies.
Under the agreement, Andelyn will use MyoAAV plasmids for research and development services, including screening potential gene therapy candidates and preparing for IND-enabling studies. The license also allows Andelyn to sublicense the plasmids to clients for internal research purposes.
Matt Niloff, Chief Commercial Officer at Andelyn, stated, “Our license from the Broad Institute furthers our goal of providing the industry access to critical tools and capabilities that facilitate the development of innovative therapies.” He highlighted that the MyoAAVs will enhance the efficiency and reduce costs in gene therapy processes.
The inclusion of MyoAAV plasmids is expected to drive forward sustainable manufacturing practices and provide more accessible treatments for patients. Andelyn continues to leverage its capabilities in Columbus, Ohio, to advance gene therapies for both rare and prevalent diseases.
Overview of outsourcing trends 
